The association of CD46, SLAM and CD209 cellular receptor gene SNPs with variations in measles vaccine-induced immune responses: A replication study and examination of novel polymorphisms

Human Heredity

Volumn 72, Issue 3, 2011, Pages 206-223

  Ovsyannikova, Inna G ^a,b   Haralambieva, Iana H ^a   Vierkant, Robert A ^a   O'Byrne, Megan M ^a   Jacobson, Robert M ^c   Poland, Gregory A ^a,b,c  

^a MAYO CLINIC   (United States)

^b Program in Translational Immunovirology and Biodefense   (United States)

^c Mayo Clinic ^*  (United States)

Author keywords

CD209; CD46; Measles vaccine immunity; Measles virus receptors; Replication study; Single nucleotide polymorphisms; SLAM; SNP

Indexed keywords

ALPHA INTERFERON; CD150 ANTIGEN; CD209 ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 6; MEASLES ANTIBODY; MEASLES MUMPS RUBELLA VACCINE; MEASLES VACCINE; MEMBRANE COFACTOR PROTEIN; TUMOR NECROSIS FACTOR ALPHA;

ADOLESCENT; ADULT; AFRICAN AMERICAN; ALLELE; ANTIBODY TITER; ARTICLE; CAUCASIAN; CELLULAR IMMUNITY; CHILD; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HERITABILITY; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOGENETICS; INTRON; MALE; NORMAL HUMAN; RECEPTOR GENE; REPLICATION STUDY; SCHOOL CHILD; SINGLE NUCLEOTIDE POLYMORPHISM;

ADOLESCENT; AFRICAN AMERICANS; ANTIGENS, CD; ANTIGENS, CD46; CELL ADHESION MOLECULES; CHILD; COHORT STUDIES; DEMOGRAPHY; ENZYME-LINKED IMMUNOSPOT ASSAY; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENETIC ASSOCIATION STUDIES; HAPLOTYPES; HUMANS; IMMUNITY; IMMUNITY, HUMORAL; INTERFERON-GAMMA; LECTINS, C-TYPE; MALE; MEASLES; MEASLES VACCINE; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, CELL SURFACE; REPRODUCIBILITY OF RESULTS; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

MEASLES VIRUS; RUBELLA;

EID: 80855144267     PISSN: 00015652     EISSN: 14230062     Source Type: Journal    
DOI: 10.1159/000331585     Document Type: Article

References (55)

1. Bouche FB, Ertl OT, Muller CP: Neutralizing B cell response in measles. Viral Immunol 2002; 15: 451-471.
2. Moss WJ, Griffin DE: Global measles elimination. Nat Rev Microbiol 2006; 4: 900-908. (Pubitemid 44768252)
3. Permar SR, Klumpp SA, Mansfield KG, Kim WK, Gorgone DA, Lifton MA, Williams KC, Schmitz JE, Reimann KA, Axthelm MK, Polack FP, Griffin DE, Letvin NL: Role of CD8(+) lymphocytes in control and clearance of measles virus infection of rhesus monkeys. J Virol 2003; 77: 4396-4400. (Pubitemid 36350977)
4. Andres O, Obojes K, Kim KS, ter Muelen V, Schneider-Schaulies J: CD46-and CD150-independent endothelial cell infection with wild-type measles viruses. J Gen Virol 2003; 84: 1189-1197. (Pubitemid 36603297)
5. Hsu EC, Lorio C, Sarangi F, Khine AA, Richardson CD: CDw150(SLAM) is a receptor for a lymphotropic strain of measles virus and may account for the immunosuppressive properties of this virus. Virology 2001; 279: 9-21. (Pubitemid 34160994)
6. Manchester M, Naniche D, Stehlet T: CD46 as a measles receptor: form follows function. Virology 2000; 274: 5-10. (Pubitemid 30650676)
7. Dorig RE, Marcil A, Chopra A, Richardson CD: The human CD46 molecule is a receptor for measles virus (Edmonston strain). Cell 1993; 75: 295-305. (Pubitemid 23320293)
8. Naniche D, Varior-Krishnan G, Cervoni F, Wild TF, Rossi B, Rabourdin-Combe C, Gerlier D: Human membrane cofactor protein (CD46) acts as a cellular receptor for measles virus. J Virol 1993; 67: 6025-6032. (Pubitemid 23277513)
9. Yanagi Y, Ono N, Tatsuo H, Hashimoto K, Minagawa H: Measles virus receptor SLAM (CD150). Virology 2002; 299: 155-161. (Pubitemid 35356591)
10. Schneider U, von Messling V, Devaux P, Cattaneo R: Efficiency of measles virus entry and dissemination through different receptors. J Virol 2002; 76: 7460-7467. (Pubitemid 34760968)
11. de Witte L, Abt M, Schneider-Schaulies S, van Kooyk Y, Geijtenbeek TB: Measles virus targets DC-SIGN to enhance dendritic cell infection. J Virol 2006; 80: 3477-3486.
12. Castro AG, Hauser TM, Cocks BG, Abrams J, Zurawski S, Churakova T, Zonin F, Robinson D, Tangye SG, Aversa G, Nichols KE, De Vries JE, Lanier LL, O'Garra A: Molecular and functional characterization of mouse signaling lymphocytic activation molecule (SLAM): differential expression and responsiveness in Th1 and Th2 cells. J Immunol 1999; 163: 5860-5870.
13. Punnonen J, Cocks BG, Carballido JM, Bennett B, Peterson D, Aversa G, De Vries JE: Soluble and membrane-bound forms of signaling lymphocytic activation molecule (SLAM) induce proliferation and Ig synthesis by activated human B lymphocytes. J Exp Med 1997; 185: 993-1004. (Pubitemid 27136792)
14. Aversa G, Carballido J, Punnonen J, Chang CC, Hauser T, Cocks BG, De Vries JE: SLAM and its role in T cell activation and Th cell responses. Immunol Cell Biol 1997; 75: 202-205. (Pubitemid 27191865)
15. Henning G, Kraft MS, Derfuss T, Pirzer R, Saint-Basile G, Aversa G, Fleckenstein B, Meinl E: Signaling lymphocytic activation molecule (SLAM) regulates T cellular cytotoxicity. Eur J Immunol 2001; 31: 2741-2750. (Pubitemid 32898742)
16. de Witte L, de Vries RD, van der Vlist M, Yuksel S, Litjens M, de Swart RL, Geijtenbeek TB: DC-SIGN and CD150 have distinct roles in transmission of measles virus from dendritic cells to T-lymphocytes. PLoS Pathog 2008; 4:e1000049.
17. Ono N, Tatsuo H, Tanaka K, Minagawa H, Yanagi Y: V domain of human SLAM (CDw150) is essential for its function as a measles virus receptor. J Virol 2001; 75: 1594-1600S.
18. Tatsuo H, Ono N, Tanaka K, Yanagi Y: SLAM (CDw150) is a cellular receptor for measles virus. Nature 2000; 406: 893-897. (Pubitemid 30664265)
19. Ferrand V, Li C, Romeo G, Yin L: Absence of SLAM mutations in EBV-associated lymphoproliferative disease patients. J Med Virol 2003; 70: 131-136. (Pubitemid 36368875)
20. Casasnovas JM, Larvie M, Stehle T: Crystal structure of two CD46 domains reveals an extended measles virus-binding surface. EMBO J 1999; 18: 2911-2922. (Pubitemid 29255600)
21. Manchester M, Eto DS, Valsamakis A, Liton PB, Fernandez-Munoz R, Rota PA, Bellini WJ, Forthal DN, Oldstone MB: Clinical isolates of measles virus use CD46 as a cellular receptor. J Virol 2000; 74: 3967-3974. (Pubitemid 30214401)
22. Gerlier D, Trescol-Bi'mont MC, Varior-Krishnan G, Naniche D, Fugier-Vivier I, Rabourdin-Combe C: Efficient major histocompatibility complex class II-restricted presentation of measles virus relies on hemagglutinin- mediated targeting to its cellular receptor human CD46 expressed by murine B cells. J Exp Med 1994; 179: 353-358. (Pubitemid 24013004)
23. Erlenhofer C, Duprex WP, Rima BK, ter Meulen V, Schneider-Schaulies J: Analysis of receptor (CD46, CD150) usage by measles virus. J Gen Virol 2002; 83: 1431-1436. (Pubitemid 34591337)
24. Dhiman N, Poland GA, Cunningham JM, Jacobson RM, Ovsyannikova IG, Vierkant RA, Wu Y, Pankratz VS: Variations in measles vaccine-specific humoral immunity by polymorphisms in SLAM and CD46 measles virus receptors. J Allergy Clin Immunol 2007; 120: 666-672. (Pubitemid 47320741)
25. Ovsyannikova IG, Dhiman N, Haralambieva IH, Vierkant RA, O'Byrne MM, Jacobson RM, Poland GA: Rubella vaccine-induced cellular immunity: evidence of associations with polymorphisms in the Toll-like, vitamin A and D receptors, and innate immune response genes. Hum Genet 2010; 127: 207-221.
26. Ovsyannikova IG, Haralambieva IH, Dhiman N, O'Byrne MM, Pankratz VS, Jacobson RM, Poland GA: Polymorphisms in the vitamin A receptor and innate immunity genes influence the antibody response to rubella vaccination. J Infect Dis 2010; 201: 207-213.
27. Haralambieva IH, Dhiman N, Ovsyannikova IG, Vierkant RA, Pankratz VS, Jacobson RM, Poland GA: 2′-5′-Oligoadenylate synthetase single-nucleotide polymorphisms and haplotypes are associated with variations in immune responses to rubella vaccine. Hum Immunol 2010; 71: 383-391.
28. Dhiman N, Haralambieva IH, Kennedy RB, Vierkant RA, O'Byrne MM, Ovsyannikova IG, Jacobson RM, Poland GA: SNP/haplotype associations in cytokine and cytokine receptor genes and immunity to rubella vaccine. Immunogenetics 2010; 62: 197-210.
29. Pankratz VS, Vierkant RA, O'Byrne MM, Ovsyannikova IG, Poland GA: Associations between SNPs in candidate immune-relevant genes and rubella antibody levels: a multigenic assessment. BMC Immunol 2010; 11: 48.
30. Haralambieva IH, Ovsyannikova IG, Vierkant RA, Poland GA: Development of a novel efficient fluorescence-based plaque reduction microneutralization assay for measles immunity. Clin Vaccine Immunol 2008; 15: 1054-1059. (Pubitemid 352018321)
31. Ovsyannikova IG, Haralambieva IH, Vierkant RA, Pankratz VS, Jacobson RM, Poland GA: The role of polymorphisms in Toll-like receptors and their associated intracellular signaling genes in measles vaccine immunity. Hum Genet 2011; 130: 547-561.
32. Ryan JE, Ovsyannikova IG, Poland GA: Detection of measles virus-specific IFN-gamma-secreting T-cells by ELISPOT; in Kalyuzhyny AE (ed): Handbook of ELISPOT: Methods and Protocols. Totowa, Humana Press Inc, 2005, pp 207-217.
33. Carlson CS, Eberle MA, Rieder MJ, Yi Q, Kruglyak L, Nickerson DA: Selecting a maximally informative set of single-nucleotide polymorphisms for association analyses using linkage disequilibrium. Am J Hum Genet 2004; 74: 106-120. (Pubitemid 38085242)
34. den Dunnen JT, Antonarakis SE: Nomenclature for the description of human sequence variations. Hum Genet 2001; 109: 121-124. (Pubitemid 32743202)
35. Haralambieva IH, Dhiman N, Ovsyannikova IG, Vierkant RA, Pankratz VS, Jacobson RM, Poland GA: Oligoadenylate synthetase single-nucleotide polymorphisms and haplotypes are associated with variations in immune responses to rubella vaccine. Hum Immunol 2010; 71: 383-391.
36. Weir BS: Genetic Data Analysis II: Methods for Discrete Population Genetic Data, ed 2. Sinauer Associates, Inc. 1996, pp 98-99.
37. Barrett JC, Fry B, Maller J, Daly MJ: Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005; 21: 263-265. (Pubitemid 40202029)
38. Schaid DJ, Rowland CM, Tines DE, Jacobson RM, Poland GA: Score tests for association between traits and haplotypes when linkage phase is ambiguous. Am J Hum Genet 2002; 70: 425-434. (Pubitemid 34112296)
39. Jordan WJ, Eskdale J, Boniotto M, Rodia M, Kellner D, Gallagher G: Modulation of the human cytokine response by interferon lambda-1 (IFN-lambda1/IL-29). Genes Immun 2007; 8: 13-20. (Pubitemid 46164287)
40. Tan PL, Jacobson RM, Poland GA, Jacobsen SJ, Pankratz SV: Twin studies of immunogenicity-determining the genetic contribution to vaccine failure. Vaccine 2001; 19: 2434-2439. (Pubitemid 32234254)
41. Poland GA, Ovsyannikova IG, Jacobson RM, Vierkant RA, Jacobsen SJ, Pankratz VS, Schaid DJ: Identification of an association between HLA class II alleles and low antibody levels after measles immunization. Vaccine 2001; 20: 430-438. (Pubitemid 32973785)
42. Ovsyannikova IG, Pankratz VS, Vierkant RA, Jacobson RM, Poland GA: Human leukocyte antigen haplotypes in the genetic control of immune response to measlesmumps-rubella vaccine. J Infect Dis 2006; 193: 655-663. (Pubitemid 43273493)
43. Ovsyannikova IG, Jacobson RM, Ryan JE, Vierkant RA, Pankratz VS, Poland GA: Human leukocyte antigen and interleukin 2, 10 and 12p40 cytokine responses to measles: is there evidence of the HLA effect? Cytokine 2006; 36: 173-179. (Pubitemid 46275467)
44. Dhiman N, Ovsyannikova IG, Cunningham JM, Vierkant RA, Kennedy RB, Pankratz VS, Poland GA, Jacobson RM: Associations between measles vaccine immunity and single nucleotide polymorphisms in cytokine and cytokine receptor genes. J Infect Dis 2007; 195: 21-29. (Pubitemid 44958223)
45. Pasare C, Medzhitov R: Toll-like receptors and acquired immunity. Semin Immunol 2004; 16: 23-26. (Pubitemid 38147430)
46. Medzhitov R: Toll-like receptors and innate immunity. Nat Rev Immunol 2001; 1: 135-145. (Pubitemid 33741967)
47. Poland GA, Ovsyannikova IG, Jacobson RM: Application of pharmacogenomics to vaccines. Pharmacogenomics 2009; 10: 837-852.
48. Poland GA, Ovsyannikova IG, Jacobson RM, Smith DI: Heterogeneity in vaccine immune response: the role of immunogenetics and the emerging field of vaccinomics. Clin Pharmacol Ther 2007; 82: 653-664. (Pubitemid 350114830)
49. Cocks BG, Chang CC, Carballido JM, Yssel H, De Vries JE, Aversa G: A novel receptor involved in T-cell activation. Nature 1995; 376: 260-263.
50. Fiorentino DF, Zlotnik A, Vieira P, Mosmann TR, Howard M, Moore KW, O'Garra A: IL-10 acts on the antigen-presenting cell to inhibit cytokine production by Th1 cells. J Immunol 1991; 146: 3444-3451.
51. Chorley BN, Wang X, Campbell MR, Pittman GS, Noureddine MA, Bell DA: Discovery and verification of functional single nucleotide polymorphisms in regulatory genomic regions: current and developing technologies. Mutat Res 2008; 659: 147-157.
52. Chanock SJ, Manolio T, Boehnke M, Boerwinkle E, Hunter DJ, Thomas G, Hirschhorn JN, Abecasis G, Altshuler D, Bailey-Wilson JE, Brooks LD, Cardon LR, Daly M, Donnelly P, Fraumeni JF Jr, Freimer NB, Gerhard DS, Gunter C, Guttmacher AE, Guyer MS, Harris EL, Hoh J, Hoover R, Kong CA, Merikangas KR, Morton CC, Palmer LJ, Phimister EG, Rice JP, Roberts J, Rotimi C, Tucker MA, Vogan KJ, Wacholder S, Wijsman EM, Winn DM, Collins FS: Replicating genotype-phenotype associations. Nature 2007; 447: 655-660. (Pubitemid 46889722)
53. Li Q, Yu K: Improved correction for population stratification in genome-wide association studies by identifying hidden population structures. Genet Epidemiol 2008; 32: 215-226. (Pubitemid 351550368)
54. Gibbs JR, Singleton A: Application of genome-wide single nucleotide polymorphism typing: simple association and beyond. PLoS Genet 2006; 2:e150.
55. Hattersley AT, McCarthy MI: What makes a good genetic association study? Lancet 2005; 366: 1315-1323. (Pubitemid 41416588)